Amuvatinib hydrochloride is an orally active multi-targeted tyrosine kinase inhibitor effective against mutant c-Kit, PDGFRalpha, Flt3, c-Met, and c-Ret. It also suppresses DNA repair by inhibiting RAD51, contributing to its anticancer activity in both cellular and animal models of various cancers.